{"cluster": 20, "subcluster": 6, "abstract_summ": "We report acute antibody responses to SARS-CoV-2 in 285 patients with COVID-19.Higher antibody responses are associated with symptomatic disease, older age, ethnicity, increased co-morbidity and higher inflammatory markers such as C Reactive Protein.We evaluated the kinetics of IgM, IgA and IgG SARS-CoV-2 antibodies in COVID-19 patients with confirmed (rRT-PCR) infection.Validation studies of serological antibody tests must be properly designed for clinical, epidemiological and Public Health objectives such as confirmation of suspected COVID-19 cases, certification of seroconversion after infection, and epidemiological surveillance.Their application in regular surveillance will clarify the duration and protective nature of humoral responses to SARS-CoV.BACKGROUND: It is unknown whether MS disease modifying therapies impact ability to mount an antibody response to SARS-CoV-2.", "title_summ": "Antibody responses to SARS-CoV-2 in patients with COVID-19.Dynamics of IgG seroconversion and pathophysiology of COVID-19 infectionsNegative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumabIgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal studyDetection of antibodies against SARS\u2010CoV\u20102 in patients with COVID\u201019", "title_abstract_phrases": "Their application in regular surveillance will clarify the duration and protective nature of humoral responses to SARS-CoV.Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumabBACKGROUND: It is unknown whether MS disease modifying therapies impact ability to mount an antibody response to SARS-CoV-2.Antibody responses to SARS-CoV-2 in patients with COVID-19.We report acute antibody responses to SARS-CoV-2 in 285 patients with COVID-19.IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal studyValidation studies of serological antibody tests must be properly designed for clinical, epidemiological and Public Health objectives such as confirmation of suspected COVID-19 cases, certification of seroconversion after infection, and epidemiological surveillance.We evaluated the kinetics of IgM, IgA and IgG SARS-CoV-2 antibodies in COVID-19 patients with confirmed (rRT-PCR) infection.Higher antibody responses are associated with symptomatic disease, older age, ethnicity, increased co-morbidity and higher inflammatory markers such as C Reactive Protein."}